Over $12 Million Bet On TD Holdings? Check Out These 3 Penny Stocks Insiders Are Buying

The Federal Reserve on Wednesday raised its benchmark rate by 0.25%, marking the central bank's second consecutive policy downshift. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

 

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

 

Ensysce Biosciences

 

The Trade: Ensysce Biosciences, Inc. ENSC Director Bob G Gower bought a total of 357,143 shares at an average price of $1.40. To acquire these shares, it cost around $500 thousand.

 

What’s Happening: Ensysce Biosciences announced initiation of the final stage of its opioid overdose protection Phase 1 study.

 

What Ensysce Biosciences Does: Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs.

 

TD Holdings

 

The Trade: TD Holdings, Inc. GLG 10% owner Shuxiang Zhang acquired a total 10,000,000 shares at an average price of $1.21. The insider spent around $12.1 million to buy those shares.

 

What’s Happening: TD Holdings said on January 9, the company entered into certain securities purchase agreement with Huiwen Hu to sell an aggregate of 35 million shares of common stock at $1.21 per share.

 

What TD Holdings Does: TD Holdings Inc is engaged in commodity trading business and supply chain service business in China.

 

Check This Out: Meta Check Out 3 High-Yielding Dividend Stocks In Industrials Sector From Benzinga's Most Accurate Analysts

 

Biodesix

 

The Trade: Biodesix, Inc. BDSX Director Jack Schuler acquired a total of 10,000 shares at an average price of $2.41. To acquire these shares, it cost around $24.1 thousand.

 

What’s Happening: Biodesix, during November, announced pricing of $35.1 million upsized public offering of 30.5 million shares of common stock at a price of $1.15/share.

 

What Biodesix Does: Biodesix Inc is a data-driven diagnostic solutions company.

 

Don’t forget to check out our premarket coverage here